ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2016
[Research advances in the role of interleukin-21 in chronic hepatitis B virus infection].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients.Journal of clinical laboratory analysis · 2019Article
- Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis.Experimental and therapeutic medicine · 2017Article
- [Establishment of a cell co-culture system in accordance with the immunological characteristics of chronic HBV infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-21 (IL-21) is a cytokine mainly secreted by activated CD4+ T cells and natural killer T cells and has multiple effects. It is involved in innate and adaptive immune responses. Recent studies have shown that IL-21 can promote functional activation of various immune cells in the process of hepatitis B virus (HBV) infection, and the gene polymorphisms of IL-21 is associated with the susceptibility to HBV. In addition, the expression of IL-21 is closely associated with HV genotype, HBV clearance, HBeAg seroconversion, HBV-related liver cirrhosis, liver failure, liver cancer, and autoimmune disease. This article reviews the research advances in clinical trials with reference to the aspects above.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.